Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This report describes the treatment of eight patients with
status asthmaticus
, six of whom were already maximally treated. They were consequently treated with enoximone, a selective
phosphodiesterase
III inhibitor, in their refractory phase. Bronchodilatation in these patients was immediate. No side-effects were observed. Enoximone appears to be a valuable addition to the treatment of
status asthmaticus
. I.V. administration bypasses inhalation incapability in severe asthma. It is likely to reduce or altogether prevent the need for resorting to secondary or tertiary high-tech therapy such as mechanical ventilation or anaesthetics, thus avoiding complications, as well as for transfers to specialized intensive care units. Not only do these aspects enable substantial cost savings, but they also may spare the patient a lot of anguish and a prolonged recovery.
...
PMID:Emergency treatment of status asthmaticus with enoximone. 2463 33
In a patient with severe
status asthmaticus
, enoximone, a
phosphodiesterase
-3 inhibitor, caused immediate bronchodilation
http://bit.ly/38UYpUn.
...
PMID:Enoximone in status asthmaticus. 3228 Jun 67
